Диссертация (1140892), страница 27
Текст из файла (страница 27)
‒ 2015. ‒ T. 141, № 11. ‒ C. 2047-60.268. Randall N., Courville E. L., Baughn L., Afrin L., Ustun C. Bosutinib, a Lyn/Btk inhibitingtyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis // Am J Hematol. ‒2015. ‒ T. 90, № 4. ‒ C. E74.269. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., Campochiaro P., Wood J.,O'Reilly T., Meyer T. PKC412--a protein kinase inhibitor with a broad therapeutic potential //Anticancer Drug Des.
‒ 2000. ‒ T. 15, № 1. ‒ C. 17-28.270. Gotlib J., Kluin-Nelemans H. C., George T. I., Akin C., Sotlar K., Hermine O., Awan F. T.,Hexner E., Mauro M. J., Sternberg D. W., Villeneuve M., Huntsman Labed A., Stanek E. J.,152Hartmann K., Horny H. P., Valent P., Reiter A. Efficacy and Safety of Midostaurin inAdvanced Systemic Mastocytosis // N Engl J Med. ‒ 2016. ‒ T. 374, № 26. ‒ C. 2530-41.271. Gleixner K.
V., Peter B., Blatt K., Suppan V., Reiter A., Radia D., Hadzijusufovic E., Valent P.Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplasticmast cells carrying KIT D816V // Haematologica. ‒ 2013. ‒ T. 98, № 9. ‒ C. 1450-7.272. Jin B., Ding K., Pan J. Ponatinib induces apoptosis in imatinib-resistant human mast cells bydephosphorylating mutant D816V KIT and silencing beta-catenin signaling // Mol CancerTher.
‒ 2014. ‒ T. 13, № 5. ‒ C. 1217-30.273. Simon J., Lortholary O., Caillat-Vigneron N., Raphael M., Martin A., Briere J., Barete S.,Hermine O., Casassus P. Interest of interferon alpha in systemic mastocytosis. The Frenchexperience and review of the literature // Pathol Biol (Paris). ‒ 2004. ‒ T. 52, № 5. ‒ C. 294-9.274. Butterfield J. H., Li C. Y. Bone marrow biopsies for the diagnosis of systemic mastocytosis: isone biopsy sufficient? // Am J Clin Pathol. ‒ 2004. ‒ T.
121, № 2. ‒ C. 264-7.275. Barete S., Lortholary O., Damaj G., Hirsch I., Chandesris M. O., Elie C., Hamidou M., Durieu I.,Suarez F., Grosbois B., Limal N., Gyan E., Larroche C., Guillet G., Kahn J. E., Casassus P.,Amazzough K., Coignard-Biehler H., Georgin-Lavialle S., Lhermitte L., Fraitag S., CanioniD., Dubreuil P., Hermine O. Long-term efficacy and safety of cladribine (2-CdA) in adultpatients with mastocytosis // Blood. ‒ 2015. ‒ T. 126, № 8. ‒ C. 1009-16; quiz 1050.276. Ustun C., Gotlib J., Popat U., Artz A., Litzow M., Reiter A., Nakamura R., Kluin-Nelemans H.C., Verstovsek S., Gajewski J., Perales M. A., George T., Shore T., Sperr W., Saber W., KotaV., Yavuz A.
S., Pullarkat V., Rogosheske J., Hogan W., Van Besien K., Hagglund H., DamajG., Arock M., Horny H. P., Metcalfe D. D., Deeg H. J., Devine S., Weisdorf D., Akin C.,Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in AdvancedSystemic Mastocytosis // Biol Blood Marrow Transplant. ‒ 2016. ‒ T. 22, № 8.
‒ C. 13481356.277. Gotlib J., Pardanani A., Akin C., Reiter A., George T., Hermine O., Kluin-Nelemans H.,Hartmann K., Sperr W. R., Brockow K., Schwartz L. B., Orfao A., Deangelo D. J., Arock M.,Sotlar K., Horny H. P., Metcalfe D. D., Escribano L., Verstovsek S., Tefferi A., Valent P.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWGMRT) & European Competence Network on Mastocytosis (ECNM) consensus responsecriteria in advanced systemic mastocytosis // Blood. ‒ 2013. ‒ T.
121, № 13. ‒ C. 2393-401.278. Gonzalez-de-Olano D., Alvarez-Twose I., Vega A., Orfao A., Escribano L. Venomimmunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis //Immunotherapy. ‒ 2011. ‒ T. 3, № 5. ‒ C. 637-51.153279. Sokol K. C., Ghazi A., Kelly B. C., Grant J. A. Omalizumab as a desensitizing agent andtreatment in mastocytosis: a review of the literature and case report // J Allergy Clin ImmunolPract. ‒ 2014. ‒ T. 2, № 3. ‒ C.
266-70.280. Carter M. C., Robyn J. A., Bressler P. B., Walker J. C., Shapiro G. G., Metcalfe D. D.Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemicmastocytosis // J Allergy Clin Immunol. ‒ 2007. ‒ T. 119, № 6. ‒ C. 1550-1.281.
Kibsgaard L., Skjold T., Deleuran M., Vestergaard C. Omalizumab induced remission ofidiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis // Acta DermVenereol. ‒ 2014. ‒ T. 94, № 3. ‒ C. 363-4.282. Kontou-Fili K., Filis C. I., Voulgari C., Panayiotidis P. G.
Omalizumab monotherapy for beesting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectablespecific IgE // Ann Allergy Asthma Immunol. ‒ 2010. ‒ T. 104, № 6. ‒ C. 537-9.283. Lieberoth S., Thomsen S. F. Cutaneous and gastrointestinal symptoms in two patients withsystemic mastocytosis successfully treated with omalizumab // Case Rep Med. ‒ 2015. ‒ T.2015. ‒ C. 903541.284. Beck L. A., Marcotte G. V., MacGlashan D., Togias A., Saini S. Omalizumab-induced reductionsin mast cell Fce psilon RI expression and function // J Allergy Clin Immunol. ‒ 2004. ‒ T. 114,№ 3. ‒ C. 527-30.285. Siebenhaar F., von Tschirnhaus E., Hartmann K., Rabenhorst A., Staubach P., Peveling-OberhagA., Wagner N., Martus P., Carter M. C., Metcalfe D.
D., Church M. K., Maurer M., Weller K.Development and validation of the mastocytosis quality of life questionnaire: MC-QoL //Allergy. ‒ 2016. ‒ T. 71, № 6. ‒ C. 869-77.286. Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI)--a simple practical measurefor routine clinical use // Clin Exp Dermatol. ‒ 1994. ‒ T. 19, № 3. ‒ C. 210-6.287. Beck A. T., Ward C. H., Mendelson M., Mock J., Erbaugh J. An inventory for measuringdepression // Arch Gen Psychiatry. ‒ 1961. ‒ T.
4. ‒ C. 561-71.288. Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale // Acta Psychiatr Scand. ‒1983. ‒ T. 67, № 6. ‒ C. 361-70.289. Kristensen T., Broesby-Olsen S., Vestergaard H., Bindslev-Jensen C., Moller M. B. Serumtryptase correlates with the KIT D816V mutation burden in adults with indolent systemicmastocytosis // Eur J Haematol. ‒ 2013. ‒ T. 91, № 2. ‒ C. 106-11.290. Pyatilova P., Teplyuk N., Olisova O., Kovrigina A., Gadaev I., Kolkhir P. Efficacy of PUVA inRussian patients with mastocytosis: a case series and review of literature // Int J Dermatol.
‒2018. ‒ T. 57, № 9. ‒ C. e59-e64.154291. Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology andpathology // Am J Cancer Res. ‒ 2013. ‒ T. 3, № 2. ‒ C. 159-72.292. Sousa-Pinto B., Fonseca J. A., Gomes E. R. Frequency of self-reported drug allergy: A systematicreview and meta-analysis with meta-regression // Ann Allergy Asthma Immunol. ‒ 2017. ‒ T.119, № 4. ‒ C. 362-373 e2.293. Gomes E. R., Demoly P.
Epidemiology of hypersensitivity drug reactions // Curr Opin AllergyClin Immunol. ‒ 2005. ‒ T. 5, № 4. ‒ C. 309-16.294. Passali D., Cingi C., Staffa P., Passali F., Muluk N. B., Bellussi M. L. The International Study ofthe Allergic Rhinitis Survey: outcomes from 4 geographical regions // Asia Pac Allergy.
‒2018. ‒ T. 8, № 1. ‒ C. e7.295. Tejedor Alonso M. A., Moro Moro M., Mugica Garcia M. V. Epidemiology of anaphylaxis // ClinExp Allergy. ‒ 2015. ‒ T. 45, № 6. ‒ C. 1027-39.296. Metcalfe D. D. Classification and diagnosis of mastocytosis: current status // J Invest Dermatol. ‒1991. ‒ T. 96, № 3 Suppl. ‒ C. 2S-4S; discussion 4S, 60S-65S.297. Brockow K., Scott L. M., Worobec A. S., Kirshenbaum A., Akin C., Huber M. M., Metcalfe D.D.
Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlationwith clinical patterns of disease // Arch Dermatol. ‒ 2002. ‒ T. 138, № 6. ‒ C. 785-90.298. Sperr W. R., Valent P. Diagnosis, progression patterns and prognostication in mastocytosis //Expert Rev Hematol.
‒ 2012. ‒ T. 5, № 3. ‒ C. 261-74.299. Moura D. S., Sultan S., Georgin-Lavialle S., Barete S., Lortholary O., Gaillard R., Hermine O.Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations todepression // PLoS One. ‒ 2012.
‒ T. 7, № 6. ‒ C. e39468.300. Moura D. S., Georgin-Lavialle S., Gaillard R., Hermine O. Neuropsychological features of adultmastocytosis // Immunol Allergy Clin North Am. ‒ 2014. ‒ T. 34, № 2. ‒ C. 407-22.301. Smith J. H., Butterfield J. H., Pardanani A., DeLuca G. C., Cutrer F. M. Neurologic symptomsand diagnosis in adults with mast cell disease // Clin Neurol Neurosurg.
‒ 2011. ‒ T. 113, № 7.‒ C. 570-4.302. Guillaume N., Desoutter J., Chandesris O., Merlusca L., Henry I., Georgin-Lavialle S., Barete S.,Hirsch I., Bouredji D., Royer B., Gruson B., Lok C., Sevestre H., Mentaverri R., Brazier M.,Meynier J., Hermine O., Marolleau J. P., Kamel S., Damaj G. Bone complications ofmastocytosis: a link between clinical and biological characteristics // Am J Med. ‒ 2013. ‒ T.126, № 1. ‒ C. 75 e1-7.303. Rossini M., Zanotti R., Bonadonna P., Artuso A., Caruso B., Schena D., Vecchiato D., BonifacioM., Viapiana O., Gatti D., Senna G., Riccio A., Passalacqua G., Pizzolo G., Adami S. Bone155mineral density, bone turnover markers and fractures in patients with indolent systemicmastocytosis // Bone.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
